vs
Side-by-side financial comparison of Armour Residential REIT, Inc. (ARR) and 4D Molecular Therapeutics, Inc. (FDMT). Click either name above to swap in a different company.
4D Molecular Therapeutics, Inc. is the larger business by last-quarter revenue ($85.1M vs $50.4M, roughly 1.7× Armour Residential REIT, Inc.). Armour Residential REIT, Inc. runs the higher net margin — 420.2% vs 22.8%, a 397.5% gap on every dollar of revenue. On growth, 4D Molecular Therapeutics, Inc. posted the faster year-over-year revenue change (8508900.0% vs 297.9%). Over the past eight quarters, 4D Molecular Therapeutics, Inc.'s revenue compounded faster (5412.6% CAGR vs 108.0%).
Armour Residential REIT, Inc. is a U.S.-based real estate investment trust that primarily invests in agency residential mortgage-backed securities guaranteed by U.S. government-sponsored entities. It focuses on generating consistent long-term net income for shareholders via strategic asset management and active interest rate risk mitigation.
4D Molecular Therapeutics is a clinical-stage biotechnology company specializing in the research and development of targeted adeno-associated virus (AAV) gene therapies. Its core product candidates address unmet medical needs in ophthalmology, cardiology, and pulmonary disease segments, serving global patient populations with rare and common hard-to-treat conditions.
ARR vs FDMT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $50.4M | $85.1M |
| Net Profit | $211.7M | $19.4M |
| Gross Margin | — | — |
| Operating Margin | — | 17.3% |
| Net Margin | 420.2% | 22.8% |
| Revenue YoY | 297.9% | 8508900.0% |
| Net Profit YoY | 555.9% | 139.1% |
| EPS (diluted) | $2.43 | $0.43 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $50.4M | $85.1M | ||
| Q3 25 | $38.5M | $90.0K | ||
| Q2 25 | $33.1M | $15.0K | ||
| Q1 25 | $36.3M | $14.0K | ||
| Q4 24 | $12.7M | $1.0K | ||
| Q3 24 | — | $3.0K | ||
| Q2 24 | $7.0M | $5.0K | ||
| Q1 24 | — | $28.0K |
| Q4 25 | $211.7M | $19.4M | ||
| Q3 25 | $159.3M | $-56.9M | ||
| Q2 25 | $-75.6M | $-54.7M | ||
| Q1 25 | $27.3M | $-48.0M | ||
| Q4 24 | $-46.4M | — | ||
| Q3 24 | — | $-43.8M | ||
| Q2 24 | $-48.4M | $-35.0M | ||
| Q1 24 | — | $-32.4M |
| Q4 25 | — | 17.3% | ||
| Q3 25 | — | -67983.3% | ||
| Q2 25 | — | -396373.3% | ||
| Q1 25 | — | -383007.1% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -1704400.0% | ||
| Q2 24 | — | -849120.0% | ||
| Q1 24 | — | -136200.0% |
| Q4 25 | 420.2% | 22.8% | ||
| Q3 25 | 413.5% | -63195.6% | ||
| Q2 25 | -228.4% | -364386.7% | ||
| Q1 25 | 75.2% | -342657.1% | ||
| Q4 24 | -366.8% | — | ||
| Q3 24 | — | -1461433.3% | ||
| Q2 24 | -693.8% | -699060.0% | ||
| Q1 24 | — | -115717.9% |
| Q4 25 | $2.43 | $0.43 | ||
| Q3 25 | $1.49 | $-1.01 | ||
| Q2 25 | $-0.94 | $-0.98 | ||
| Q1 25 | $0.32 | $-0.86 | ||
| Q4 24 | $-0.91 | — | ||
| Q3 24 | — | $-0.79 | ||
| Q2 24 | $-1.05 | $-0.63 | ||
| Q1 24 | — | $-0.66 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $63.3M | $402.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $2.3B | $505.7M |
| Total Assets | $21.0B | $566.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $63.3M | $402.7M | ||
| Q3 25 | $44.2M | $305.1M | ||
| Q2 25 | $141.2M | $293.2M | ||
| Q1 25 | $49.1M | $321.4M | ||
| Q4 24 | $68.0M | $424.9M | ||
| Q3 24 | — | $501.9M | ||
| Q2 24 | $126.6M | $541.9M | ||
| Q1 24 | — | $525.9M |
| Q4 25 | $2.3B | $505.7M | ||
| Q3 25 | $2.1B | $369.0M | ||
| Q2 25 | $1.7B | $420.9M | ||
| Q1 25 | $1.7B | $469.7M | ||
| Q4 24 | $1.4B | $510.6M | ||
| Q3 24 | — | $552.9M | ||
| Q2 24 | $1.2B | $588.3M | ||
| Q1 24 | — | $600.6M |
| Q4 25 | $21.0B | $566.7M | ||
| Q3 25 | $19.4B | $424.0M | ||
| Q2 25 | $16.2B | $473.6M | ||
| Q1 25 | $15.5B | $515.7M | ||
| Q4 24 | $13.5B | $560.4M | ||
| Q3 24 | — | $604.0M | ||
| Q2 24 | $10.1B | $620.1M | ||
| Q1 24 | — | $629.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $124.2M | $28.6M |
| Free Cash FlowOCF − Capex | — | $28.5M |
| FCF MarginFCF / Revenue | — | 33.5% |
| Capex IntensityCapex / Revenue | — | 0.1% |
| Cash ConversionOCF / Net Profit | 0.59× | 1.47× |
| TTM Free Cash FlowTrailing 4 quarters | — | $-109.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $124.2M | $28.6M | ||
| Q3 25 | $-37.8M | $-46.5M | ||
| Q2 25 | $25.0M | $-43.4M | ||
| Q1 25 | $101.5M | $-47.8M | ||
| Q4 24 | $261.5M | $-134.6M | ||
| Q3 24 | — | $-29.4M | ||
| Q2 24 | $27.1M | $-30.2M | ||
| Q1 24 | — | $-29.1M |
| Q4 25 | — | $28.5M | ||
| Q3 25 | — | $-46.6M | ||
| Q2 25 | — | $-43.4M | ||
| Q1 25 | — | $-48.4M | ||
| Q4 24 | — | $-138.4M | ||
| Q3 24 | — | $-31.2M | ||
| Q2 24 | — | $-30.6M | ||
| Q1 24 | — | $-29.8M |
| Q4 25 | — | 33.5% | ||
| Q3 25 | — | -51765.6% | ||
| Q2 25 | — | -289620.0% | ||
| Q1 25 | — | -345635.7% | ||
| Q4 24 | — | -13837100.0% | ||
| Q3 24 | — | -1038966.7% | ||
| Q2 24 | — | -611840.0% | ||
| Q1 24 | — | -106421.4% |
| Q4 25 | — | 0.1% | ||
| Q3 25 | — | 101.1% | ||
| Q2 25 | — | 440.0% | ||
| Q1 25 | — | 4507.1% | ||
| Q4 24 | — | 378600.0% | ||
| Q3 24 | — | 59266.7% | ||
| Q2 24 | — | 6980.0% | ||
| Q1 24 | — | 2535.7% |
| Q4 25 | 0.59× | 1.47× | ||
| Q3 25 | -0.24× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 3.71× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
